Short communication, Note
MTHFR C 677T Mutation and 4G/5G PAI-1 Polymorphism in Patient With Polycystic Ovarian Syndrome
Branko Radaković
Marina Šprem Goldštajn
Abstract
Combined oral contraceptives (Ocs) are the most commonly used androgen supresors and the treatment of choice for
menstrual dysfunction in women with polycystic ovarian syndrome (PCOs). Although OCs have remained popular due
to their convenience and effectiveness, there have been continuing concerns about adverse effects. The OCs have long been
known to incur and increased risk of venous thromboembolism especially in carriers of common inherited thromboembolic
defects. Factor V Leiden, prothrombin factor G20210A polymorphism, MTHFR (C677T) mutation and 4G/5G
polymorphism of the PAI-1 gene account for the majority of thromboembolic events in association with oral contraceptive
use. The aim of the article is to present woman with unrecognized inherited thrombophilia who was treated with OCs
due to PCOs signs.
Keywords
MTHFR C 677T mutation; 4G/5G PAI-1 polymorphism; polycystic ovarian syndrome; oral contraceptives
Hrčak ID:
26908
URI
Publication date:
3.9.2007.
Visits: 3.054 *